Controlled drug release

Transdermal drug delivery systems (TDDS), particularly in the form of patches, have emerged as a major breakthrough in pharmaceutical science, enabling drugs to be administered directly through the skin in a non-invasive manner. These systems allow controlled and sustained drug release, leading to improved therapeutic efficiency. Unlike conventional oral route Skin, TDDS bypass first-pass metabolism and help maintain consistent plasma drug concentrations. Progress in this field has been driven by the development of innovative materials, novel polymers, advanced permeation enhancers, and smart delivery platforms. The incorporation of nanotechnology has broadened the applicability of TDDS, making it possible to deliver molecules that were previously unsuitable for transdermal administration. Deeper understanding of skin physiology and its barrier functions has facilitated the design of next-generation patches utilizing nanocarriers, microemulsions, and stimuli-responsive polymers. Additionally, approaches such as microneedle arrays, iontophoresis, and sonophoresis have significantly boosted drug permeation across the skin. Several marketed products highlight the practical success of these technologies, while ongoing research continues to refine delivery strategies and evaluation techniques. Overall, the evolution of TDDS has led to more effective, convenient, and patient-friendly therapeutic options, positioning them as a promising platform for addressing complex treatment challenges and catering to diverse healthcare needs in the future.

The intricate structures of the eye's posterior segment pose significant challenges for effective drug delivery in the treatment of various diseases. Current modalities, such as topical and intraocular medications, often face barriers that limit their penetration, residence time, and bioavailability. This necessitates frequent dosing, impacting patient compliance and quality of life. Suprachoroidal injection emerges as a novel and promising approach for targeted drug delivery to the posterior segment. The suprachoroidal space, situated between the sclera and choroid, provides a minimally invasive route for medication delivery, offering advantages like higher drug concentrations, increased bioavailability, and prolonged action. This method also mitigates the risk of adverse events associated with other routes, particularly corticosteroid-related complications. This review discusses the potential of suprachoroidal injection, highlighting its benefits in overcoming anatomical barriers and improving therapeutic outcomes. However, further research is crucial to address existing challenges, including technological advancements, injection techniques, and considerations of cost and accessibility. Exploring synergies with biotech products, gene therapies, and cell-based treatments can pave the way for personalized and effective strategies in managing posterior segment eye diseases.